Pharmaceuticals News and Research

RSS

New biosensor device may help in combating cancer

A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.

5 Nov 2009

Third-quarter financial results for the year 2009 announced by Biovail

Biovail Corporation today announced financial results for the three-month and nine-month periods ended September 30, 2009. To the extent that this news release contains forward-looking statements, investors are cautioned that these statements are based on the Company’s current views, and actual outcomes are not certain.

5 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share.

5 Nov 2009

FDA approves the New Drug Application for Pennsaid Topical Solution

Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.

5 Nov 2009

Middlebrook Pharmaceuticals announces financial and operational results for third quarter 2009

MiddleBrook Pharmaceuticals, Inc. today announced its financial and operational results for the quarter ended Sept. 30, 2009.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Third quarter 2009 financial results announced by Aradigm

Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2009 and recent highlights.

5 Nov 2009

King Pharmaceuticals announces total revenues of $463M for the third quarter of 2009

King Pharmaceuticals, Inc. announced today that total revenues were $463 million during the third quarter ended September 30, 2009, compared to $388 million in the third quarter of 2008. The Company reported net income of $42 million and diluted earnings per share of $0.17 during the third quarter of 2009, compared to net income of $82 million and diluted earnings per share of $0.34 in the third quarter of the prior year.

5 Nov 2009

Pennsaid Topical Solution approved by FDA

Covidien, a leading global provider of healthcare products, and Nuvo Research Inc. (TSX:NRI), a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid® Topical Solution (diclofenac sodium topical solution) 1.5% w/w.

5 Nov 2009

Aureus Pharma to provide new AurSCOPE knowledge databases for sanofi-aventis’ R&D division

Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces today the extension of its knowledge database agreement with sanofi-aventis research & development for an additional three-year term.

5 Nov 2009

Phase Forward, Quotient Clinical sign multi-year agreement

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year agreement with Quotient Clinical, which specializes in early development services for a broad range of pharmaceutical and biotech customers.

5 Nov 2009

Researchers demonstrate that Aeolus Pharmaceuticals' AEOL 10150 protects lungs from chlorine gas

Aeolus Pharmaceuticals, Inc. reported that researchers from National Jewish Health and McGill University have completed a series of preliminary studies demonstrating that AEOL 10150 protects lungs from chlorine gas exposure in mice.

5 Nov 2009

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008.

5 Nov 2009

Abraxis Health dedicates its new manufacturing facility in Phoenix

Abraxis Health, a fully-integrated personalized healthcare division of Abraxis BioScience, Inc., today announced the dedication of its new manufacturing facility in Phoenix, Arizona. The state of the art biopharma manufacturing plant represents a $70 million investment by LA-based Abraxis, and will create up to 200 high tech jobs.

5 Nov 2009

SCYNEXIS receives payment as part of pharmaceutical discovery program with Merial

Merial Limited and SCYNEXIS, Inc. announced today that SCYNEXIS has earned a payment for meeting certain milestones in its multi-year research collaboration with Merial Limited, which began in 2005.

5 Nov 2009

Green tea holds hope for prevention of oral cancer

Green tea extract has shown promise as cancer prevention agent for oral cancer in patients with a pre-malignant condition known as oral leukoplakia, according to researchers at The University of Texas M. D. Anderson Cancer Center.

5 Nov 2009

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Raptor Pharmaceutical Corp., today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

5 Nov 2009

Patient enrollment in three late-stage clinical trials completed

Inspire Pharmaceuticals, Inc. announced today patient enrollment is complete in three of its late-stage clinical trials.

5 Nov 2009

Tetracycline-like compound raises hope for treatment of spinal muscular atrophy

A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants. This is the finding of a research collaboration involving Adrian Krainer, Ph.D., of Cold Spring Harbor Laboratory (CSHL) and scientists from Paratek Pharmaceuticals and Rosalind Franklin University of Medicine and Science.

5 Nov 2009

Pharmaceuticals News and Research

New biosensor device may help in combating cancer

Third-quarter financial results for the year 2009 announced by Biovail

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

FDA approves the New Drug Application for Pennsaid Topical Solution

Middlebrook Pharmaceuticals announces financial and operational results for third quarter 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Third quarter 2009 financial results announced by Aradigm

King Pharmaceuticals announces total revenues of $463M for the third quarter of 2009

Pennsaid Topical Solution approved by FDA

Aureus Pharma to provide new AurSCOPE knowledge databases for sanofi-aventis’ R&D division

Phase Forward, Quotient Clinical sign multi-year agreement

Researchers demonstrate that Aeolus Pharmaceuticals' AEOL 10150 protects lungs from chlorine gas

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Abraxis Health dedicates its new manufacturing facility in Phoenix

SCYNEXIS receives payment as part of pharmaceutical discovery program with Merial

Green tea holds hope for prevention of oral cancer

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Patient enrollment in three late-stage clinical trials completed

Tetracycline-like compound raises hope for treatment of spinal muscular atrophy

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring